Tvardi receives FDA pre-IND feedback for TTI-109 in inflammatory bowel disease
Tvardi Therapeutics announced receipt of FDA written responses to its pre-IND meeting request for TTI-109, the company's next-generation oral STAT3 inhibitor for inflammatory bowel disease. The FDA agreed that the proposed nonclinical studies are appropriate to support a Phase 2 trial and provided guidance on dosing, study design, and patient selection. The company plans to submit an IND in 2027, with Phase 2 initiation subject to FDA clearance and additional funding availability. New analysis of Phase 1 exposur...
Read source-backed brief